AU Patent

AU2024227231A1 — Remdesivir treatment methods

Assigned to Gilead Sciences Inc · Expires 2024-10-31 · 2y expired

What this patent protects

Methods of treating viral infections in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a compound of Formula Ia. In some embodiments, the subject is not administered chloroquine, desethylchloroquine, hydroxychloro…

USPTO Abstract

Methods of treating viral infections in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a compound of Formula Ia. In some embodiments, the subject is not administered chloroquine, desethylchloroquine, hydroxychloroquine, desethylhydroxychloroquine, and bisdesethylhydroxychloroquine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024227231A1
Jurisdiction
AU
Classification
—
Expires
2024-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.